Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
Use of GLP-1 RAs/SGLT2is in patients with T2D and ASCVD has increased in recent years in the USA, but remains suboptimal given the prevalence of ASCVD and its high morbidity and mortality.
Authors
- Xi Tan (ORCID: https://orcid.org/0000-0002-2409-5927)
- Charles E. Leonard (ORCID: https://orcid.org/0000-0002-5092-9657)
- Rhonda L. Bohn (ORCID: https://orcid.org/0000-0002-4883-275X)
- Aaron A. King (ORCID: https://orcid.org/0000-0001-6159-3207)
- Adam de Havenon (ORCID: https://orcid.org/0000-0001-8178-8597)
- Neil Dhopeshwarkar (ORCID: https://orcid.org/0000-0001-6305-256X)
- Katherine Dea
Institutions
- Baptist Health System (US)
- Yale University (US)
- Novo Nordisk (United States) (US)
- Cambridge Econometrics (United Kingdom) (GB)
- Our Bodies Ourselves (US)
- TriNetX (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- BMJ Open Diabetes Research & Care
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/bmjdrc-2024-004431
- Citations
- 33
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 11.45
Funders
- Eli Lilly and Company
- MannKind Corporation
- ACCP Foundation
- Dexcom
- Novo Nordisk
- Astellas Pharma
- National Institutes of Health